Quest PharmaTech Management
Management criteria checks 2/4
Quest PharmaTech's CEO is Madi Madiyalakan, appointed in Aug 2006, has a tenure of 17.25 years. total yearly compensation is CA$269.00K, comprised of 79.9% salary and 20.1% bonuses, including company stock and options. directly owns 1.89% of the company’s shares, worth $139.99K. The average tenure of the management team and the board of directors is 19 years and 2.3 years respectively.
Key information
Madi Madiyalakan
Chief executive officer
CA$269.0k
Total compensation
| CEO salary percentage | 79.9% |
| CEO tenure | 17.3yrs |
| CEO ownership | 1.9% |
| Management average tenure | 19yrs |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jul 31 2023 | n/a | n/a | -CA$21m |
| Apr 30 2023 | n/a | n/a | -CA$11m |
| Jan 31 2023 | CA$269k | CA$215k | -CA$7m |
| Oct 31 2022 | n/a | n/a | -CA$78m |
| Jul 31 2022 | n/a | n/a | -CA$87m |
| Apr 30 2022 | n/a | n/a | -CA$86m |
| Jan 31 2022 | CA$189k | CA$40k | -CA$85m |
| Oct 31 2021 | n/a | n/a | CA$68m |
| Jul 31 2021 | n/a | n/a | CA$81m |
| Apr 30 2021 | n/a | n/a | CA$83m |
| Jan 31 2021 | CA$270k | CA$40k | CA$190m |
| Oct 31 2020 | n/a | n/a | CA$111m |
| Jul 31 2020 | n/a | n/a | CA$106m |
| Apr 30 2020 | n/a | n/a | CA$102m |
| Jan 31 2020 | n/a | n/a | -CA$6m |
| Oct 31 2019 | n/a | n/a | -CA$5m |
| Jul 31 2019 | n/a | n/a | -CA$5m |
| Apr 30 2019 | n/a | n/a | -CA$5m |
| Jan 31 2019 | CA$105k | CA$30k | -CA$4m |
| Oct 31 2018 | n/a | n/a | -CA$5m |
| Jul 31 2018 | n/a | n/a | -CA$6m |
| Apr 30 2018 | n/a | n/a | -CA$5m |
| Jan 31 2018 | CA$127k | CA$26k | -CA$5m |
| Oct 31 2017 | n/a | n/a | -CA$3m |
| Jul 31 2017 | n/a | n/a | -CA$3m |
| Apr 30 2017 | n/a | n/a | -CA$3m |
| Jan 31 2017 | CA$63k | CA$63k | -CA$2m |
Compensation vs Market: Madi's total compensation ($USD196.14K) is below average for companies of similar size in the US market ($USD740.57K).
Compensation vs Earnings: Madi's compensation has increased whilst the company is unprofitable.
CEO
Madi Madiyalakan
17.3yrs
Tenure
CA$269,000
Compensation
Dr. Ragupathy Madiyalakan, Ph D., also known as Madi, serves as Chief Executive Officer at OncoQuest Inc. He has been the Chief Executive Officer of Quest PharmaTech, Inc. since August 2006. Dr. Madiyalaka...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 17.3yrs | CA$269.00k | 1.89% CA$ 140.0k | |
| Chief Financial Officer | 18.8yrs | CA$101.17k | 1.08% CA$ 80.1k | |
| Head of Investor Relations & Corporate Communications | 19.1yrs | no data | no data | |
| Vice President of Corporate Development | no data | CA$37.94k | no data | |
| Vice President of Product Development | 21.4yrs | CA$15.00k | no data |
19.0yrs
Average Tenure
Experienced Management: QPTF.F's management team is seasoned and experienced (19 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 19.4yrs | CA$269.00k | 1.89% CA$ 140.0k | |
| Chairman | less than a year | no data | no data | |
| Independent Director | 2.3yrs | CA$47.00k | no data | |
| Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | 18.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 18.3yrs | no data | no data | |
| Chairman of Scientific Advisory Board | 13.3yrs | no data | no data | |
| Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.3yrs | CA$28.00k | 0.21% CA$ 15.3k |
2.3yrs
Average Tenure
Experienced Board: QPTF.F's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.